Skip to contentpdufa.bio

lasofoxifene

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

lasofoxifene is a LeonaBio, Inc. program in ER+/HER2-, ESR1-mutated metastatic breast cancer. Its next catalyst is a Readout in Q4 2027.

LONA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: ER+/HER2-, ESR1-mutated metastatic breast cancer. Sponsor: LeonaBio, Inc. (LONA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027LONA

Questions

When is lasofoxifene's next FDA decision or readout?

The next tracked catalyst for lasofoxifene is a Readout in Q4 2027.

What happened at lasofoxifene's most recent FDA decision?

No FDA decision for lasofoxifene is in our archive yet.

What is lasofoxifene used for?

In our records lasofoxifene is under review or in development for ER+/HER2-, ESR1-mutated metastatic breast cancer.

Who makes lasofoxifene?

LeonaBio, Inc. (LONA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.